Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 9/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.46 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5795295 | 0.98 | KCNN4 (0.61) | KCNN4MAPTKMT2AMEN1NPC1 | |
| SCHEMBL22655984 | 0.83 | KMT2A (0.63) | MAPTKMT2ACES2CES1KIF11 | |
| SCHEMBL23003615 | 0.82 | KCNN4 (0.50) | KCNN4MAPTKMT2AMEN1NPC1 | |
| SCHEMBL5936056 | 0.82 | MAPT (0.68) | MAPTKMT2AMEN1NPC1HTT | |
| SCHEMBL10885402 | 0.81 | KCNN4 (0.61) | KCNN4MAPTKMT2AMEN1NPC1 | |
| SCHEMBL1421745 | 0.80 | APP (0.49) | KCNN4MAPTKMT2AMEN1NPC1 | |
| SCHEMBL7873851 | 0.80 | MAPT (0.65) | KCNN4MAPTKMT2ANPC1RAB9A | |
| SCHEMBL2332626 | 0.80 | MAPT (0.65) | KCNN4MAPTKMT2AMEN1NPC1 | |
| SCHEMBL9768982 | 0.80 | KMT2A (0.48) | KCNN4MAPTKMT2AMEN1NPC1 | |
| SCHEMBL3135954 | 0.80 | MAPT (0.65) | KCNN4MAPTKMT2AALDH1A1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1729158-A | Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2006-02-01 | — | — | CN | claimed |
| US-20250302803-A1 | ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-10-02 | — | — | US | disclosed |
| US-12357610-B2 | Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-07-15 | — | — | US | disclosed |
| US-20230414566-A1 | ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-12-28 | — | — | US | disclosed |
| US-11806333-B2 | Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-11-07 | — | — | US | disclosed |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | PLIANT THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200360342-A1 | ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2020-11-19 | — | — | US | disclosed |
| US-20110160459-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | SOLVAY PHARMACEUTICALS, B.V. | 2011-06-30 | — | — | US | disclosed |
| EP-2203427-A2 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLES AS CANNABINOID CB1 RECEPTOR AGONISTS | Abbott Healthcare Products B.V. (NL) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009037244-A2 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLES AS CANNABINOID CB1 RECEPTOR AGONISTS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-03-26 | — | — | WO | disclosed |
| EP-1764099-A2 | Diaminoalcohol derivatives for the treatment of Alzheimer, malaria, HIV | Speedel Experimenta AG (CH) | 2007-03-21 | — | — | EP | disclosed |
| WO-2005090304-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | disclosed |
| EP-1177175-A2 | HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS PDE 4 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2002-02-06 | — | — | EP | disclosed |
| US-6200993-B1 | ASTHMA; ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA & CO. (CA) | 2001-03-13 | — | — | US | disclosed |
| WO-2000068198-A2 | HETEROSUBSTITUTED PYRIDINE DERIVATIVES AS PDE 4 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360342-A1 | ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES | AADAC, GABRB2, GABARAPL2 | KCNN4 463/4885MAPT 1500/4885KMT2A 1290/4885 |
| US-20110160459-A1 | 5-ARYL-4,5-DIHYDRO-(1H)-PYRAZOLINES AS CANNABINOID CB1 RECEPTOR AGONISTS | CNR1, CNR2, HTR5A | KCNN4 996/4885MAPT 3215/4885KMT2A 3126/4885 |
| US-12357610-B2 | Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures | AADAC, GABRB2, GABARAPL2 | KCNN4 463/4885MAPT 1500/4885KMT2A 1290/4885 |
| US-11180494-B2 | Substituted amino acids as integrin inhibitors | ITGB6, ITGA1, ITGB1 | KCNN4 4750/4885MAPT 3524/4885KMT2A 2632/4885 |
| US-20250302803-A1 | ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES | AADAC, GABRB2, GABARAPL2 | KCNN4 463/4885MAPT 1500/4885KMT2A 1290/4885 |
| US-20230414566-A1 | ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES | AADAC, GABRB2, GABARAPL2 | KCNN4 463/4885MAPT 1500/4885KMT2A 1290/4885 |
| US-11806333-B2 | Aryl-substituted acetamide and pyrrolidin-2-one derivatives and their use for the treatment of seizures | AADAC, GABRB2, GABARAPL2 | KCNN4 463/4885MAPT 1500/4885KMT2A 1290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.